Last C$0.08 CAD
Change Today +0.01 / 15.38%
Volume 103.0K
DMA On Other Exchanges
As of 12:59 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - C$1.10
52 Week Low
12/2/14 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.5K
Executive Vice President
Total Annual Compensation: C$234.0K
Vice-President of Research
Total Annual Compensation: C$177.0K
Vice President of Finance
Total Annual Compensation: C$74.5K
Consulting Chief Medical Officer
Total Annual Compensation: C$11.8K
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

DiaMedica Inc. Announces Restructuring Plans Including Number of Staff Layoffs, Including John Savage as Chief Financial Officer

DiaMedica Inc. announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the company going forward. The company's restructuring includes a number of staff layoffs, including John Savage as Chief Financial Officer. DiaMedica plans to continue working with Mr. Savage on a part-time, consultancy basis.

DiaMedica Inc. Announces Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes

DiaMedica Inc. announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in patients with type 2 diabetes. DM199 is a recombinant form of the human tissue kallikrein-1 protein (rhKLK1). The company's Phase IIa clinical trial met its primary endpoint. The study demonstrated that DM199 was safe and well tolerated following administration to patients by subcutaneous injection (beneath the skin). Based on the Company's initial assessment, DM199 treatment did not achieve the secondary objectives of improvement in glucose control. The randomized, placebo-controlled, double-blind study enrolled a total of 37 patients with type 2 diabetes, 35 of whom completed the entire 28-day study. Prior to the study, patients completed a 28-day wash out of their diabetes medications and then were sequestered for the month-long study. Patients were randomly assigned to receive subcutaneous doses of either 3 or 15 (micro)g/kg of DM199 or placebo once every 72 hours.

Diamedica Inc. Approves Amendments to the Articles of Incorporation and By-Laws

Diamedica Inc. at its annual general and special meeting of shareholders held on July 24, 2014 approved to amend the Articles of Incorporation to consolidate the outstanding common shares on the basis of one post-consolidation common share for each two to ten pre-consolidation common shares; and approved certain amendments to the company's by-laws; and renewing the shareholder rights plan of the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.08 CAD +0.01

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at